Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEW HOPE TTX-MC138 DESERVES THE WORLDS ATTENTION FOR THE TERMINALLY ILL CANCER PATIENTS
Tomorrow is The Stars and Stripes", "Old Glory", Star-Spangled Banner" RnA Breakthrough Made in the USA
It's a full fledged war to get TTX-MC138, to the terminally ill cancer patients, we are about to witness Transcode therapeutics true power of hard work and dedication.
Blast out the news, Let’s rock and roll$$
Then I will kiss your feet… lol
What if TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and other get partnership agreement with a giant Pharma
What if TTX-MC138 gets fast track status from FDA for terminally ill cancer patients with no hope , Keep in mind they tested it already on one patient and results can follow next week
This is how I understand the proposal 4 [to grant the Board the authority to file an amendment to effect the reverse spilt in their discretion before Dec 31, 2024] see page 21-28 https://ir.transcodetherapeutics.com/static-files/2eab1bdd-3a8d-46a1-a1ad-8dfe8aa1770b 1. The primary reason for rs is to increase the stock price for the purpose of regaining $1 minimum bid requirement & raise investor interest (explained on page 22, see screen shot) 2. When the proxy material was written, the stock price was around $0.45, and the company needed a plan to increase the stock price when they appeal the decision to delist in the Hearing panel on May 14, imo. 3. On page 26, it states "The Reverse Stock Split will not be consummated, if at all, until after approval of our stockholders is obtained." So proposal 4 is to grant the Board authority to decide if R/S is needed, and if they deem so, there will be another vote [similar to last time]. Otherwise, if R/S not needed, such authority will expire by Dec 31, 2024 $RNAZ
Mark my words RNAZ'S TTX-MC138 Is the most undervalued company in all Nasdaq, It could be the next HOLO Move
This breakthrough RNA treatment has been suppressed for so long that shorts deserve to burn in hell once and for all, God bless RNAZ
Wait till the herd gets wind of this… I’m always early for a reason but 3 days is when it goes ballistic after buy in… this weekend should have more eyeballs on this. Thanks for the stock tip found this one from you on HOLO forum.. that one hits $1.50 or less it’s a buy!
Still way undervalued here, MARKET CAP
$9.26M
SHARES OUTSTANDING
6.57M
PUBLIC FLOAT
6.54M
New hope TTX-MC138 in Patients with Advanced Solid Tumors
All signs still pointing to get to about $3. After that well that’s crazy if it does
The time has come to declare The Stars and Stripes", "Old Glory", Star-Spangled Banner breakthrough for the terminally ill cancer patients
I admit I did that.sold under 2 and bought back in.
I want to party $weet$$$ pop pill$ and fly
Dear TransCode Stockholder:
I am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TransCode Therapeutics, Inc (the “Company” or “TransCode”). The Annual Meeting will be held on June 13, 2024, at 9:30 a.m., local time, at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210.
We intend to hold our Annual Meeting in person. In the event it is not possible or advisable to hold our Annual Meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication. Please monitor our annual meeting website at https://ir.transcodetherapeutics.com/annual-meeting for updated information. If you are planning to attend our Annual Meeting, please check the website one week prior to the meeting date. To ensure that your vote is counted, we encourage you to vote your shares by proxy prior to the Annual Meeting. If you decide to change your vote or if you are a stockholder of record and decide to vote in person at the Annual Meeting, your updated vote will be the vote that is counted.
At this Annual Meeting, the agenda includes:
•
election of four (4) directors, Philippe P. Calais, PharmD, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD, for one-year terms until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
?
•
approval of an amendment to the Company’s 2021 Stock Option and Incentive Plan to increase the number of shares available for issuance thereunder by 3,000,000 shares, as more fully described in this Proxy Statement (as defined below);
?
?
•
ratification of the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
?
?
•
approval of an amendment to our amended and restated certificate of incorporation, as amended (the “Charter”), to authorize our Board of Directors, or Board, if they determine that doing so is in the best interest of our shareholders, to effect a reverse stock split of our outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), at a ratio, ranging from one-for-two (1:2) to one-for-forty (1:40), with the exact ratio to be set within that range at the discretion of our Board of Directors without further approval or authorization of our stockholders;
?
?
•
approval of a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the amendment to the Company’s 2021 Stock Option and Incentive Plan proposal and the reverse stock split proposal; and
?
•
the transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
?
This 2024 Annual Meeting Proxy Statement (the “Proxy Statement”) and enclosed proxy card are first being mailed to stockholders on or about May???, 2024.
Details regarding admission to the Annual Meeting and the business to be conducted are more fully described in the accompanying Notice of 2024 Annual Meeting of Stockholders (the “Notice”) and the Proxy Statement. Stockholders of record are owners of our stock as of April 22, 2024, and are entitled to vote at our Annual Meeting and any adjournments thereof.
Read this maybe I’m wrong but it looks like RS and adding shares???
https://fintel.io/sf/us/rnaz
How many people I’m guessing bought under $1.36 ran it up $2 sold and going to buy back in knowing there are so many bag holders or long term investors now above $1.36. This should go nuts again next week waaaay above $2.00. It corrected the same day it shot up. If it recovers Monday Tuesday dip Wednesday up Thursday Friday should be a killer week
Yo G' Management want to meet up in with shareholders in person this year, must have something exciting in the pipeline,
Dear TransCode Stockholder:
I am pleased to invite you to attend the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TransCode Therapeutics, Inc (the “Company” or “TransCode”). The Annual Meeting will be held on June 13, 2024, at 9:30 a.m., local time, at the offices of Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210.
We intend to hold our Annual Meeting in person. In the event it is not possible or advisable to hold our Annual Meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication. Please monitor our annual meeting website at https://ir.transcodetherapeutics.com/annual-meeting for updated information. If you are planning to attend our Annual Meeting, please check the website one week prior to the meeting date. To ensure that your vote is counted, we encourage you to vote your shares by proxy prior to the Annual Meeting. If you decide to change your vote or if you are a stockholder of record and decide to vote in person at the Annual Meeting, your updated vote will be the vote that is counted
AI DON’T LIE…
https://coincodex.com/stock/RNAZ/price-prediction/
Look at the Green and volume! Anyone over $1.36 is a bag holder and won’t sell or buy more this bad boy is not done….
shares rolling into Class A combo out there now. CUSIP changes, shorts must close and no matter how much they try to hide their shorts, they go onto and remain on their books. They must close.. they'll try fuckery but they can't get the shares off their books without closing them.
Shorts need to be very carefully here, they are going to end up in hell where they belong once and for all
squeezes come after an exhaustion of selling pressure. This exhaustion can be sudden of gradual and that is the difficulty.
A better way to look at it is wait for it to happen and then cover in earnest at market. You will have bad execution, but think of the “smart money” dudes who decided to hold on and got squeezed
Yup monster buys came pouring in to shake up the tree
Shorts have to cover if they bought $2 there shares would be worth $1. Bulls run this up before RS MOASS
Don't get fooled by these Pharma tycoons they want your shares badly
This is it dude, make it or break it moment cancer breakthrough drug!!! Let’s see if it’s the real deal hollyfield cancer breakthrough
RNAZ..............................https://stockcharts.com/h-sc/ui?s=RNAZ&p=W&b=5&g=0&id=p86431144783
Why would a vote on possible R/S make this go moass. Who the hell wants a R/S split to go through,, unless you’re joking.
What a momentum killer
You better be careful. Are you sure she is a female.she just might be a him too fool dudes.i dealt with it in the past and I am still not sure what gender it really is.
First ones free… lol
Love you $weet$$$$
What happened now with these filing$ $weet$$$ Can you tell me everything ok??
Voting on a R/S June 13 THIS SHOULD MAKE THIS GO MOASS!!!!
This Amendment No. 1 (this “Proxy Statement”) amends and restates in its entirety the Definitive Proxy Statement on Schedule 14A of TransCode Therapeutics, Inc. (the “Company”) that was originally filed with the Securities and Exchange Commission on April 29, 2024 (the “Original Proxy Statement”). This Proxy Statement is being filed (i) to include a proposal to approve an amendment to our amended and restated certificate of incorporation, as amended (the “Charter”), to authorize our Board of Directors, or Board, if they determine that doing so is in the best interest of our shareholders, to effect a reverse stock split of our outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), at a ratio, ranging from one-for-two (1:2) to one-for-forty (1:40), with the exact ratio to be set within that range at the discretion of our Board without further approval or authorization of our stockholders and (ii) to include a proposal to adjourn the Annual Meeting (as defined below) to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of certain proposals in this Proxy Statement. Except as specifically discussed herein, this Proxy Statement does not otherwise modify or update any other disclosures presented in the Original Proxy Statement.
You should read this Proxy Statement in its entirety and in place of the Original Proxy Statement. The Company will print and distribute this Proxy Statement for consideration in lieu of the Original Proxy Statement.
They gotta cover sometime. Still Bullish on this one.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
1411
|
Created
|
04/27/21
|
Type
|
Free
|
Moderators MetaMonster |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |